You are here: Industry Insights > Sun Pharma

News List

Sun Pharma to buy minority stake in Israeli firm biospectrumasia
September 13, 2018
Sun Pharma will make the acquisition through a wholly owned subsidiary.
Sun Pharma reports Q1FY19 results financialexpress
August 17, 2018
Sun Pharmaceutical Industries reported financials for the first quarter ending June 30, 2018.
Sun Pharma Announces FDA Approval of Cequa americanpharmaceuticalreview
August 17, 2018
Sun Pharma has received approval for Cequa (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration (FDA). Cequa is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Sun Pharma receives EIR for Halol facility financialexpress
June 14, 2018
Sun Pharma announced that it has received the Establishment Inspection Report (EIR) from the US FDA for the inspection conducted at its Halol facility (Gujarat, India) during the period February 12-23, 2018.
Sun Pharma launches authorised generic for Welchol tabs in US financialexpress
May 21, 2018
Sun Pharmaceutical Industries including its subsidiaries and/or associate companies) announced that one of its wholly-owned subsidiaries has launched in US
FDA approves Sun Pharma’s ILUMYA for treating plaque psoriasis biospectrumasia
March 23, 2018
ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.
Sun Pharma Announces U.S. FDA Approval of ILUMYA™ (tildrakizumab-asmn) for the Treatment of Moderate biospace
March 22, 2018
Sun Pharmaceutical Industries Ltd. today announced that FDA has approved ILUMYA™ for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
Microbial contamination forces Sun Pharma to recall two lots of diabetes drug in US pharmaceutical-business-review
November 28, 2017
Sun Pharmaceutical Industries is voluntarily recalling two lots of diabetes drug Riomet in the US due to microbial contamination.
Sun Pharma posts net profit of Rs 912 crores in Q2FY18 expressbpd
November 16, 2017
According to the agreements entered into between the parties, a wholly-owned subsidiary of Sun Pharma will acquire the portfolio consisting of 14 established prescription brands from Novartis for a cash consideration of $293 million.
Sun Pharma to increase stake in Ranbaxy Malaysia to 79.5 per cent expressbpd
October 16, 2017
Sun Pharmaceutical Industries has received final nod from the US health regulator (PTI)

Previous page 1 2 3 4 5 6 7 8 9 Next page